Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa
- PMID: 19583513
- DOI: 10.1086/603527
Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa
Abstract
Objective: To determine risk factors and outcomes for patients with meropenem high-level-resistant Pseudomonas aeruginosa (MRPA) (minimum inhibitory concentration [MIC] > or = 32 microg/mL).
Design: Case-control-control.
Setting: An 867-bed urban, teaching hospital.
Patients: Fifty-eight MRPA case patients identified from an earlier P. aeruginosa study; 125 randomly selected control patients with meropenem-susceptible P. aeruginosa (MSPA) (MIC < or = 4 microg/mL), and 57 control patients without P. aeruginosa (sampled by case date/location).
Methods: Patient data, outcomes, and costs were obtained via administrative database. Cases were compared to each control group while controlling for time at risk (days between admission and culture, or entire length of stay [LOS] for patients without P. aeruginosa).
Results: A multivariable model predicted risks for MRPA versus MSPA (odds ratio [95% confidence interval]): more admissions (in the prior 12 months) (1.41 [1.15, 1.74]), congestive heart failure (2.19 [1.03, 4.68]), and Foley catheter (2.53 [1.18, 5.45]) (adj. R(2) = 0.28). For MRPA versus no P. aeruginosa, risks were age (in 5-year increments) (1.17 [1.03, 1.33]), more prior admissions (1.40 [1.08, 1.81]), and more days in the intensive care unit (1.10 [1.03, 1.18]) (adj. R(2) = 0.32). Other invasive devices (including mechanical ventilation) and previous antibiotic use (including carbapenems) were nonsignificant. MRPA mortality (31%) did not differ from that of MSPA (15%) when adjusted for time at risk (P = .15) but did from mortality without P. aeruginosa (9%) (P = .01). Median LOS and costs were greater for MRPA patients versus MSPA patients and patients without P. aeruginosa: 30 days versus 16 and 10 (P<.01) and $88,425 versus $28,620 and $22,605 (P<.01).
Conclusions: Although antibiotic use has been shown to promote resistance, our data found that prior antibiotic use was not associated with MRPA acquisition. However, admission frequency and Foley catheters were, suggesting that infection control measures are essential to reducing MRPA transmission.
Similar articles
-
Investigation of a nosocomial outbreak by alginate-producing pan-antibiotic-resistant Pseudomonas aeruginosa.Am J Infect Control. 2008 Dec;36(10):e13-8. doi: 10.1016/j.ajic.2008.07.006. Am J Infect Control. 2008. PMID: 19084158 Clinical Trial.
-
Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections.J Hosp Infect. 2004 Jun;57(2):112-8. doi: 10.1016/j.jhin.2004.03.021. J Hosp Infect. 2004. PMID: 15183240
-
Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes.Infect Control Hosp Epidemiol. 2006 Sep;27(9):893-900. doi: 10.1086/507274. Epub 2006 Aug 21. Infect Control Hosp Epidemiol. 2006. PMID: 16941312
-
Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis.Antimicrob Resist Infect Control. 2018 Jul 4;7:79. doi: 10.1186/s13756-018-0370-9. eCollection 2018. Antimicrob Resist Infect Control. 2018. PMID: 29997889 Free PMC article.
-
Pseudomonas infections among hospitalized adults in Latin America: a systematic review and meta-analysis.BMC Infect Dis. 2020 Mar 27;20(1):250. doi: 10.1186/s12879-020-04973-0. BMC Infect Dis. 2020. PMID: 32220233 Free PMC article.
Cited by
-
Risk factors, molecular epidemiology and outcomes of ertapenem-resistant, carbapenem-susceptible Enterobacteriaceae: a case-case-control study.PLoS One. 2012;7(3):e34254. doi: 10.1371/journal.pone.0034254. Epub 2012 Mar 26. PLoS One. 2012. PMID: 22461908 Free PMC article.
-
Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections.J Hosp Infect. 2010 Dec;76(4):324-7. doi: 10.1016/j.jhin.2010.05.023. J Hosp Infect. 2010. PMID: 20643497 Free PMC article.
-
Carbapenem-resistant Pseudomonas aeruginosa and carbapenem use in Japan: an ecological study.J Int Med Res. 2019 Oct;47(10):4711-4722. doi: 10.1177/0300060519864181. Epub 2019 Aug 1. J Int Med Res. 2019. PMID: 31366256 Free PMC article.
-
Evaluation of Risk Factors for Antibiotic Resistance in Patients with Nosocomial Infections Caused by Pseudomonas aeruginosa.Can J Infect Dis Med Microbiol. 2016;2016:1321487. doi: 10.1155/2016/1321487. Epub 2016 Aug 30. Can J Infect Dis Med Microbiol. 2016. PMID: 27656220 Free PMC article.
-
Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review.Antimicrob Resist Infect Control. 2019 Aug 13;8:137. doi: 10.1186/s13756-019-0590-7. eCollection 2019. Antimicrob Resist Infect Control. 2019. PMID: 31417673 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical